Loading...

Yali Dou

Title(s)Visitng Professor of Medicine
Address1441 Eastlake Ave. NTT 3416
Health Sciences Campus
Los Angeles CA 90033
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. Yali Dou is a Professor in the Department of Medicine and Department of Biochemistry and Molecular Medicine. She currently serves as Co-Leader of the Genomics and Epigenetic Regulation (GER) program at Norris Comprehensive Cancer Center.

    Prior to joining USC in June of 2020, Dr. Dou was a Professor in the Department of Pathology and Biological Chemistry at University of Michigan, Ann Arbor since October of 2006. Dr. Dou has received a number of prestigious awards including the Leukemia & Lymphoma Society Scholar Award (2012), Stand Up to Cancer IRG Award (2011), AACR Gertrude B. Elion Cancer Research Award (2010) and Dean’s Award in Basic Science at University of Michigan (2014).

    Research Interests
    Cell fate decisions are controlled by transcription factors acting in concert with epigenetic regulators, which include enzymes that carry out histone post-translational modifications. Epigenetic mechanism underlies cell fate commitment and plasticity; its dysregulation emerges as a key characteristic of human malignancies. The Dou lab uses multidisciplinary approaches to study the establishment and maintenance of gene regulatory networks, focusing on how chromatin modifications exert temporal and spatial gene regulation via transcription factors and DNA regulatory elements. The lab is also interested in the interplays between chromatin modifications and other important cellular processes, including metabolic regulation, genome stability and higher order chromatin organization. In particular, Dou lab has extensive research on the MLL/KMT2 family of histone methyltransferases. MLL/KMT2 deposit histone H3 lysine 4 methylation, which prominently marks active gene promoters and distal enhancers. The MLL/KMT2 enzymes are frequently deleted, mutated or translocated in acute leukemia, solid tumors as well as a wide spectrum of human developmental syndromes. The study will not only advance understanding of the fundamental roles of epigenetic modulators in development and diseases, but also provide critical insights into designing novel target-based therapeutic strategies for cancer treatment and regenerative medicine.

    Collapse Research 
    Collapse Research Activities and Funding
    Structural insights into the MLL core complexes
    NIH R01CA250329Aug 25, 2020 - May 31, 2025
    Role: Principal Investigator
    Enhancer Dysregulation in AML
    NIH R01CA232263Mar 1, 2019 - Jun 30, 2020
    Role: Principal Investigator
    PRDM16 function in neural development
    NIH R01NS100156Sep 1, 2016 - Aug 31, 2021
    Role: Principal Investigator
    Chromatin replication control by protein ubiquitylation
    NIH R21CA190911Aug 7, 2015 - Jul 31, 2017
    Role: Principal Investigator
    Targeting MLL3 histone methyltransferase
    NIH R01CA187004Apr 15, 2015 - Mar 31, 2018
    Role: Principal Investigator
    Cytokine-induced epigenetic changes during chronic lung disease
    NIH R01HL112897Jun 15, 2013 - May 31, 2017
    Role: Co-Principal Investigator
    Targeting the MLL-WDR5 protein-protein interaction
    NIH R01CA177307Apr 9, 2013 - Mar 31, 2018
    Role: Co-Principal Investigator
    Epigenetic Regulation of Transcription by Mixed Lineage Leukemia Protein MLL1
    NIH R01GM082856Apr 1, 2009 - Jul 9, 2014
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Histone Acetyltransferase MOF Blocks Acquisition of Quiescence in Ground-State ESCs through Activating Fatty Acid Oxidation. Cell Stem Cell. 2020 Sep 03; 27(3):441-458.e10. Khoa LTP, Tsan YC, Mao F, Kremer DM, Sajjakulnukit P, Zhang L, Zhou B, Tong X, Bhanu NV, Choudhary C, Garcia BA, Yin L, Smith GD, Saunders TL, Bielas SL, Lyssiotis CA, Dou Y. PMID: 32610040.
      View in: PubMed   Mentions: 2     Fields:    
    2. Cryo-EM structure of the human MLL1 core complex bound to the nucleosome. Nat Commun. 2019 12 05; 10(1):5540. PMID: 31804488.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    3. HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis. Cancer Cell. 2018 10 08; 34(4):643-658.e5. Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL. PMID: 30270123.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCells
    4. MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. Cell Stem Cell. 2016 Apr 07; 18(4):481-94. Zhang H, Gayen S, Xiong J, Zhou B, Shanmugam AK, Sun Y, Karatas H, Liu L, Rao RC, Wang S, Nesvizhskii AI, Kalantry S, Dou Y. PMID: 26996599.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCells
    5. Hijacked in cancer: the KMT2 (MLL) family of methyltransferases. Nat Rev Cancer. 2015 Jun; 15(6):334-46. PMID: 25998713.
      View in: PubMed   Mentions: 119     Fields:    Translation:Humans
    6. Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. Mol Cell. 2014 Jan 23; 53(2):247-61. PMID: 24389101.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    7. The histone acetyltransferase MOF is a key regulator of the embryonic stem cell core transcriptional network. Cell Stem Cell. 2012 Aug 03; 11(2):163-78. PMID: 22862943.
      View in: PubMed   Mentions: 85     Fields:    Translation:AnimalsCells